A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
Public ClinicalTrials.gov record NCT03687827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes. Participants will be treated with insulin degludec and insulin glargine during two different periods. Which treatment participants get first is decided by chance. Both medicines are approved for use in humans and available on the market. They can already be prescribed by participants' doctors. Participants will get pre-filled insulin pens to inject these insulins with. The study will last for about 41 weeks. Participants will visit the clinic 13 times and have 27 phone calls with the study doctor or study staff. At 12 of the clinic visits they will take blood samples. In order to evaluate the changes in participants' blood sugar level over time, participants will be asked to wear a small (35 millimetres (mm) x 5 mm) sensor on the back of participants' upper arm 3 times during the study. Each time participants must wear the sensor for 2 weeks. This sensor is called FreeStyle Libre Pro®. It has a very small tip which is 0.4 mm thick and is inserted 5 mm under participants' skin. Please note that participants will not be able to see the sensor readings while wearing it. The study doctor will show participants the readings when participants return to the clinic. Participants will be asked to fill in a diary in between visits. Participants will have contact with the study doctor or study staff each week. This is to adjust the dose of participants' study medicines and to ensure that participants are well. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Study identification
- NCT ID
- NCT03687827
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 498 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2, 2018 (Actual)
- Primary completion
- Dec 20, 2019 (Actual)
- Completion
- Dec 27, 2019 (Actual)
- Last update posted
- Jan 12, 2021
2018 – 2019
United States locations
- U.S. sites
- 34
- U.S. states
- 16
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Chandler | Arizona | 85224 | — |
| Novo Nordisk Investigational Site | Tucson | Arizona | 85741 | — |
| Novo Nordisk Investigational Site | Fresno | California | 93720 | — |
| Novo Nordisk Investigational Site | Lancaster | California | 93534 | — |
| Novo Nordisk Investigational Site | Northridge | California | 91325 | — |
| Novo Nordisk Investigational Site | Poway | California | 92064 | — |
| Novo Nordisk Investigational Site | Van Nuys | California | 91405 | — |
| Novo Nordisk Investigational Site | Hamden | Connecticut | 06517 | — |
| Novo Nordisk Investigational Site | Bradenton | Florida | 34201 | — |
| Novo Nordisk Investigational Site | Cooper City | Florida | 33024 | — |
| Novo Nordisk Investigational Site | Hollywood | Florida | 33024 | — |
| Novo Nordisk Investigational Site | New Port Richey | Florida | 34652 | — |
| Novo Nordisk Investigational Site | Orlando | Florida | 32825 | — |
| Novo Nordisk Investigational Site | Pembroke Pines | Florida | 33027 | — |
| Novo Nordisk Investigational Site | Skokie | Illinois | 60077 | — |
| Novo Nordisk Investigational Site | Topeka | Kansas | 66606 | — |
| Novo Nordisk Investigational Site | Lexington | Kentucky | 40503 | — |
| Novo Nordisk Investigational Site | Louisville | Kentucky | 40213 | — |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02115-5804 | — |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02118 | — |
| Novo Nordisk Investigational Site | Kalispell | Montana | 59901 | — |
| Novo Nordisk Investigational Site | New Windsor | New York | 12553 | — |
| Novo Nordisk Investigational Site | Greenville | North Carolina | 27834 | — |
| Novo Nordisk Investigational Site | Statesville | North Carolina | 28625 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45245 | — |
| Novo Nordisk Investigational Site | Toledo | Ohio | 43614 | — |
| Novo Nordisk Investigational Site | Pelzer | South Carolina | 29669 | — |
| Novo Nordisk Investigational Site | Dakota Dunes | South Dakota | 57049 | — |
| Novo Nordisk Investigational Site | Nashville | Tennessee | 37203 | — |
| Novo Nordisk Investigational Site | Amarillo | Texas | 79106 | — |
| Novo Nordisk Investigational Site | Kerrville | Texas | 78028 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78215 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78224 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78228-6205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03687827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03687827 live on ClinicalTrials.gov.